Rapid diagnostic tests (RDTs) refer to a group of diagnostics categorized by performance characteristics rather than the specific analyte or test platform. Such assays have relatively short performance times, provide results to inform clinical decision making, and enable management at the point-of-care (POC). RDTs are available in a variety of test formats and platforms for various detection targets. RDTs are designed for detecting pathogen-specific antigens or nucleic acid sequences, as well as host antibody responses against certain pathogens.

Market Dynamics:

Increasing research and development activities by the market players to develop novel product for the rapid diagnosis of infectious diseases. Moreover, the increasing prevalence of infectious diseases globally is expected to drive market growth over the forecast period. For instance, according to the data published by the Center for Disease Control and Prevention in 2019, the number of new tuberculosis cases was 8,916, and the number of new Lyme disease cases was 34,945.

Rapid Medical Diagnostic Kits Market Segmentation:

• By Test Type
• • Blood glucose monitoring test kits
  • Pregnancy test kits
  • Infectious disease test kits
  • Coagulation monitoring test kits
  • Others
• By Sample Type
• • Blood tests
  • Urine tests
  • Saliva tests
  • Others
• By End User
• • Hospitals and clinics
  • Home care settings
  • Diagnostic laboratories
• By Region
• • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Top companies in Rapid Medical Diagnostic Kits Market:
• • Abbott Laboratories
  • Roche
  • Becton, Dickinson and Company
  • Thermo Fisher Scientific
  • Quidel Corporation
  • bioMérieux SA
  • Meridian Bioscience, Inc.
  • PerkinElmer, Inc.
  • LumiraDx